Russell Investments Group, Ltd. Ngm Biopharmaceuticals Inc Transaction History

Russell Investments Group, Ltd.

$66.8 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$0.6 - $1.31 $48,318 - $105,494	-80,530 Reduced 64.88%	43,598 $37,000
Q3 2023 Nov 13, 2023	BUY	$1.05 - $3.37 $11,479 - $36,844	10,933 Added 9.66%	124,128 $132,000
Q2 2023 Aug 10, 2023	BUY	$2.44 - $4.53 $167,264 - $310,536	68,551 Added 153.55%	113,195 $293,000
Q1 2023 May 09, 2023	SELL	$3.72 - $5.4 $3,876 - $5,626	-1,042 Reduced 2.28%	44,644 $182,000
Q4 2022 Feb 08, 2023	BUY	$3.41 - $12.93 $72,817 - $276,107	21,354 Added 87.76%	45,686 $229,000
Q3 2022 Nov 04, 2022	BUY	$12.59 - $17.67 $148,964 - $209,071	11,832 Added 94.66%	24,332 $317,000
Q2 2022 Jul 29, 2022	SELL	$10.58 - $17.5 $38,966 - $64,452	-3,683 Reduced 22.76%	12,500 $160,000
Q1 2022 May 05, 2022	SELL	$13.81 - $18.6 $61,344 - $82,621	-4,442 Reduced 21.54%	16,183 $246,000
Q4 2021 Jan 21, 2022	SELL	$17.26 - $22.02 $116,591 - $148,745	-6,755 Reduced 24.67%	20,625 $364,000
Q3 2021 Nov 08, 2021	BUY	$20.15 - $26.19 $147,498 - $191,710	7,320 Added 36.49%	27,380 $574,000
Q2 2021 Aug 04, 2021	SELL	$15.06 - $30.03 $26,535 - $52,912	-1,762 Reduced 8.07%	20,060 $393,000
Q1 2021 May 10, 2021	SELL	$24.99 - $31.93 $303,378 - $387,630	-12,140 Reduced 35.75%	21,822 $633,000
Q4 2020 Feb 08, 2021	SELL	$16.21 - $31.44 $27,378 - $53,102	-1,689 Reduced 4.74%	33,962 $1.03 Million
Q3 2020 Nov 09, 2020	SELL	$15.59 - $19.97 $83,765 - $107,298	-5,373 Reduced 13.1%	35,651 $566,000
Q2 2020 Aug 05, 2020	BUY	$11.97 - $23.47 $106,556 - $208,929	8,902 Added 27.71%	41,024 $807,000
Q1 2020 May 06, 2020	BUY	$10.0 - $19.51 $321,220 - $626,700	32,122 New	32,122 $396,000

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account